Beleaguered by its disastrous launch of Alzheimer’s drug Aduhelm (aducanumab), Biogen was able to muster some good news for investors this week, including a new opt-in to co-develop and co-market mosunetuzumab, a promising Roche drug.
The opt-in could prove to be a lifeline for Biogen, and builds on a long-running revenue stream the US company...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
